Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Lifts Import Duties On Human Immunoglobulin And Vaccine

This article was originally published in PharmAsia News

Executive Summary

China's Ministry of Finance announced that the current 3 percent import duties on antiserum, human vaccines, cultured microorganisms (excluding yeast) and four types of related immunoglobulins is now lifted effective June 1 through Dec. 31. Even though the adjustment will reduce import costs, analysts see limited impact because local enterprises dominate the domestic vaccine business, while the low-priced immunoglobulin market will not attract MNCs. Many industry experts believe the policy mainly aims to meet the demands of the recent earthquake relief. However, according to the China Chamber of Commerce of Medicines & Health Products Importers & Exporters, the government's original intention is to alleviate the supply-demand conflict of products caused by a rising consumer price index. (Click here for more - Chinese Language)

You may also be interested in...



What Justice Ginsburg’s Death Means For Pharma

A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.

‘Wrong Move’: Gottlieb Blasts Azar’s Perceived Regulatory Power Play Over FDA; HHS On Defense

The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”

US FDA Races To List Essential Medicines For Domestic Manufacture By White House Deadline

With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel